Methods and compositions using Klotho-FGF fusion polypeptides
The present invention is directed to fusion polypeptides comprising a Klotho protein or an active fragment thereof and FGF23 or an active fragment thereof.
1. A fusion polypeptide comprising, in order from N-terminus to C-terminus, a polypeptide comprising the sequence of amino acids 34 to 982 of SEQ ID NO: 19; one or more linkers; and a polypeptide comprising the sequence of amino acids 1000 to 1228 of SEQ ID NO: 19,
wherein the fusion polypeptide is capable of activating Egr-1.
2. The fusion polypeptide of claim 1 , further comprising a signal peptide.
3. A pharmaceutical composition comprising the fusion polypeptide of claim 1 and a pharmaceutically acceptable carrier.
4. The fusion polypeptide of claim 1 , wherein the one or more linkers comprise one or more polypeptide linkers.
5. A nucleic acid comprising a sequence that encodes a fusion polypeptide comprising, in order from N-terminus to C-terminus, a polypeptide comprising the sequence of amino acids 34 to 982 of SEQ ID NO: 19; one or more linkers; and a polypeptide comprising the sequence of amino acids 1000 to 1228 of SEQ ID NO: 19,
wherein the fusion polypeptide is capable of activating Egr-1.
6. A host cell containing the nucleic acid of claim 5 .
7. A vector comprising the nucleic acid of claim 5 .
8. A fusion polypeptide comprising, in order from N-terminus to C-terminus, a polypeptide consisting of the sequence of amino acids 34 to 982 of SEQ ID NO: 19; one or more linkers; and a polypeptide consisting of the sequence of amino acids 1000 to 1228 of SEQ ID NO: 19,
wherein the fusion polypeptide is capable of activating Egr-1.
9. The fusion polypeptide of claim 8 , wherein the one or more linkers comprise one or more polypeptide linkers.
10. The fusion polypeptide of claim 8 , further comprising a signal peptide.
11. A pharmaceutical composition comprising the fusion polypeptide of claim 8 and a pharmaceutically acceptable carrier.